Press Releases

Shanghai, China, October 14, 2024 – In the global biopharmaceutical industry, the innovation and production of antibody-drug conjugates (ADCs) and other bioconjugates(XDCs) are increasingly recognized as critical drivers of industry growth, offering transformative benefits for patients. WuXi XDC, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in ADCs and XDCs, today announced a significant milestone in its partnership with Pharmadule Morimatsu, a leader in modular facilities and solutions. The partnership has led to the successful delivery of state-of-the-art modular production facilities, including the first batch of nearly 100 modules, to WuXi XDC’s Singapore manufacturing site. This achievement underscores WuXi XDC’s sustained efforts to strengthen global production capabilities, its long-term commitment to clients and the industry, and unwavering dedication to meeting the evolving demands in ADC/XDC space.

Advanced Modular Fabrication for ADC Manufacturing Needs

WuXi XDC’s Singapore manufacturing facility, located in Tuas Biomedical Park, incorporates the world’s leading integrated design concept for ADC/XDC drug production. The main plant, comprising of over 200 modules supplied by Pharmadule Morimatsu, will enable seamless production of drug substances (DS) and drug products (DP) at clinical and commercial scales. The facility is also equipped with quality control (QC) laboratories, Manufacturing Science and Technology (MSAT) innovation labs, warehousing, and other essential support functions. Designed with process flexibility at its core, this state-of-the-art facility features a world-class multi-product manufacturing line, capable of meeting the full spectrum of ADC/XDC drug development and manufacturing requirements. WuXi XDC’s Singapore site is on track to be operational by late 2025.

Innovative Technology to Ensure Safety and Quality

One of the key challenges in ADC/XDC manufacturing is preventing cross-contamination while maintaining high safety standards. To address this, the facility employs special design to ensure the high quality of each batch of product and the safety of operators, meeting the stringent requirements for the production of ADCs and XDCs.

Dr. Jimmy Li, CEO of WuXi XDC, remarked on the achievement, “The successful shipment of this modular facility marks a significant step forward in our collaboration with Pharmadule Morimatsu, reflecting our broader vision of addressing the increasing global demand for ADC and bioconjugate therapies. It highlights our commitment to expanding world-class manufacturing capabilities while advancing our dual-sourcing strategy, ensuring our global clients have scalable access to high-quality manufacturing solutions. ”

Mr.Daoquan Li, CEO of Morimatsu Pharmadule (China) stated on the collaboration: “Leveraging our extensive experience in global modular facility delivery, we proudly support the development of WuXi XDC’s advanced ADC manufacturing facility in Singapore. The modular design enhances both productivity and flexibility, enabling WuXi XDC to further expand its global manufacturing capabilities. We are committed to continuing our support of WuXi XDC in advancing the construction of its Singapore site, and to collaborating further in contributing to the growth of the biopharmaceutical industry.”

About WuXi XDC

WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

Contacts

Investor: wuxixdc.ir@wuxibiologics.com

Media: wuxixdc_pr@wuxibiologics.com

BD: wuxixdc_info@wuxibiologics.com

About Morimatsu LifeSciences

Morimatsu LifeSciences is a key business unit of Morimatsu International Holding Co. Ltd. (stock code: 2155.HK), serving industries such as pharmaceuticals, biopharmaceuticals, and fast-moving consumer goods (FMCG). The company offers customers core equipment, value-added services, and smart modular factory solutions, with a focus on stainless steel process systems, disposable systems, and laboratory solutions.

About Pharmadule Morimatsu

Pharmadule, a globally recognised provider of modular facility solutions, has successfully delivered more than 80 pharmaceutical and biopharmaceutical production facilities since its founding in 1986. It has also completed over 300 engineering designs and validations. Acquired by Morimatsu in 2011, Pharmadule continues to integrate plants and processes to provide high-quality, rapid delivery solutions for global clients. For more information about Pharmadule Morimatsu, please visit:www.pharmadule.com